Neuralicorn (西湖灵犀)

Neuralicorn operates at the intersection of brain-computer interfaces, medical devices, and neurotechnology. Its stated focus on language-based neuroprosthetics and Chinese-language neural decoding gives it a specific application emphasis within the broader BCI field. The product descriptions combine signal acquisition, on-chip processing, stimulation, and decoding, rather than presenting a decoding interface alone. The described hardware includes a 64-channel low-power acquisition chip, a dual-mode high-voltage stimulation chip, and an integrated chip with 24 acquisition and 24 stimulation channels. That system-level approach could appeal to research and development teams seeking connected hardware and software for neural experimentation, while the stated use cases include rehabilitation research and clinical pathway exploration. Its differentiation is therefore best assessed from its stated product scope and language-decoding focus, not from comparative performance, clinical validation, market share, or regulatory evidence, for which information is limited.

The available indicators point to an early-stage company moving from technology development toward research validation and potential clinical pathway exploration. Neuralicorn was founded in 2022 and has one recorded financing round: a pre-seed round announced on Jun 8, 2026, involving Nanjing Innovation Capital Group, Qizhen Fund, Addor Capital, and MSA Capital. Its described product set spans a 64-channel low-power neural acquisition chip, a dual-mode high-voltage stimulation chip, an integrated 24-channel acquisition and 24-channel stimulation chip, and a Chinese-language neural decoding system. The company lists a recruitment email, which indicates an avenue for hiring, but provides no specific roles or employee-growth figures beyond a 1–10 employee range. The June 2026 financing is the clearest inflection point in the available timeline.